These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
347 related articles for article (PubMed ID: 32005073)
1. Will oral semaglutide be used to reduce cardiovascular risk in subjects with type 2 diabetes instead of subcutaneous semaglutide? Doggrell SA Expert Opin Biol Ther; 2020 May; 20(5):489-492. PubMed ID: 32005073 [No Abstract] [Full Text] [Related]
2. Dose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2/3a, randomised, controlled trial. Yamada Y; Katagiri H; Hamamoto Y; Deenadayalan S; Navarria A; Nishijima K; Seino Y; Lancet Diabetes Endocrinol; 2020 May; 8(5):377-391. PubMed ID: 32333875 [TBL] [Abstract][Full Text] [Related]
3. Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. Husain M; Birkenfeld AL; Donsmark M; Dungan K; Eliaschewitz FG; Franco DR; Jeppesen OK; Lingvay I; Mosenzon O; Pedersen SD; Tack CJ; Thomsen M; Vilsbøll T; Warren ML; Bain SC; N Engl J Med; 2019 Aug; 381(9):841-851. PubMed ID: 31185157 [TBL] [Abstract][Full Text] [Related]
4. Oral semaglutide versus injectable glucagon-like peptide-1 receptor agonists: a cost of control analysis. Hansen BB; Nuhoho S; Ali SN; Dang-Tan T; Valentine WJ; Malkin SJP; Hunt B J Med Econ; 2020 Jun; 23(6):650-658. PubMed ID: 31990244 [No Abstract] [Full Text] [Related]
5. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial. Pratley R; Amod A; Hoff ST; Kadowaki T; Lingvay I; Nauck M; Pedersen KB; Saugstrup T; Meier JJ; Lancet; 2019 Jul; 394(10192):39-50. PubMed ID: 31186120 [TBL] [Abstract][Full Text] [Related]
6. Subcutaneous semaglutide (NN9535) for the treatment of type 2 diabetes. Hedrington MS; Tsiskarishvili A; Davis SN Expert Opin Biol Ther; 2018 Mar; 18(3):343-351. PubMed ID: 29431519 [TBL] [Abstract][Full Text] [Related]
7. Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials. Husain M; Bain SC; Holst AG; Mark T; Rasmussen S; Lingvay I Cardiovasc Diabetol; 2020 Sep; 19(1):156. PubMed ID: 32998732 [TBL] [Abstract][Full Text] [Related]
8. Cardiovascular Safety and Benefits of Semaglutide in Patients With Type 2 Diabetes: Findings From SUSTAIN 6 and PIONEER 6. Nauck MA; Quast DR Front Endocrinol (Lausanne); 2021; 12():645566. PubMed ID: 33854484 [TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial. Mosenzon O; Blicher TM; Rosenlund S; Eriksson JW; Heller S; Hels OH; Pratley R; Sathyapalan T; Desouza C; Lancet Diabetes Endocrinol; 2019 Jul; 7(7):515-527. PubMed ID: 31189517 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of once-weekly semaglutide for the treatment of type 2 diabetes. Tan X; Cao X; Zhou M; Zou P; Hu J Expert Opin Investig Drugs; 2017 Sep; 26(9):1083-1089. PubMed ID: 28741970 [TBL] [Abstract][Full Text] [Related]
11. Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials. Aroda VR; Ahmann A; Cariou B; Chow F; Davies MJ; Jódar E; Mehta R; Woo V; Lingvay I Diabetes Metab; 2019 Oct; 45(5):409-418. PubMed ID: 30615985 [TBL] [Abstract][Full Text] [Related]
12. Oral semaglutide in patients with type 2 diabetes and cardiovascular disease, renal impairment, or other comorbidities, and in older patients. Mosenzon O; Miller EM; Warren ML Postgrad Med; 2020 Nov; 132(sup2):37-47. PubMed ID: 32815439 [TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): an open-label, randomised, active-controlled, phase 3a trial. Yabe D; Nakamura J; Kaneto H; Deenadayalan S; Navarria A; Gislum M; Inagaki N; Lancet Diabetes Endocrinol; 2020 May; 8(5):392-406. PubMed ID: 32333876 [TBL] [Abstract][Full Text] [Related]
14. A new era for oral peptides: SNAC and the development of oral semaglutide for the treatment of type 2 diabetes. Aroda VR; Blonde L; Pratley RE Rev Endocr Metab Disord; 2022 Oct; 23(5):979-994. PubMed ID: 35838946 [TBL] [Abstract][Full Text] [Related]
15. Efficacy, safety and cardiovascular outcomes of once-daily oral semaglutide in patients with type 2 diabetes: The PIONEER programme. Thethi TK; Pratley R; Meier JJ Diabetes Obes Metab; 2020 Aug; 22(8):1263-1277. PubMed ID: 32267058 [TBL] [Abstract][Full Text] [Related]
16. Oral Semaglutide: A Review of the First Oral Glucagon-Like Peptide 1 Receptor Agonist. Bucheit JD; Pamulapati LG; Carter N; Malloy K; Dixon DL; Sisson EM Diabetes Technol Ther; 2020 Jan; 22(1):10-18. PubMed ID: 31436480 [TBL] [Abstract][Full Text] [Related]
17. Clinical Perspectives on the Use of Subcutaneous and Oral Formulations of Semaglutide. Gallwitz B; Giorgino F Front Endocrinol (Lausanne); 2021; 12():645507. PubMed ID: 34267725 [TBL] [Abstract][Full Text] [Related]
18. Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes: A Randomized Clinical Trial. Davies M; Pieber TR; Hartoft-Nielsen ML; Hansen OKH; Jabbour S; Rosenstock J JAMA; 2017 Oct; 318(15):1460-1470. PubMed ID: 29049653 [TBL] [Abstract][Full Text] [Related]
19. Oral Semaglutide, the First Ingestible Glucagon-Like Peptide-1 Receptor Agonist: Could It Be a Magic Bullet for Type 2 Diabetes? Kim HS; Jung CH Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576096 [TBL] [Abstract][Full Text] [Related]
20. Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: Rationale, design and patient baseline characteristics for the PIONEER 6 trial. Bain SC; Mosenzon O; Arechavaleta R; Bogdański P; Comlekci A; Consoli A; Deerochanawong C; Dungan K; Faingold MC; Farkouh ME; Franco DR; Gram J; Guja C; Joshi P; Malek R; Merino-Torres JF; Nauck MA; Pedersen SD; Sheu WH; Silver RJ; Tack CJ; Tandon N; Jeppesen OK; Strange M; Thomsen M; Husain M Diabetes Obes Metab; 2019 Mar; 21(3):499-508. PubMed ID: 30284349 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]